Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cell ImpactOSTO:CI -7.38% Equity-to-Asset is 0.75 as of Jun. 2026, which is 5% below its 10-year median of 0.79. The stock has 7 warning signs investors should review. Among 3,087 Industrial Products companies, Cell Impact ranks better than 81.76% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cell Impact's Total Stockholders Equity for the quarter that ended in Jun. 2026 was kr102.14 Mil. Cell Impact's Total Assets for the quarter that ended in Jun. 2026 was kr135.93 Mil.
Therefore, Cell Impact's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.75.
The historical rank and industry rank for Cell Impact's Equity-to-Asset or its related term are showing as below:
OSTO:CI'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.11 Med: 0.79 Max: 0.88
Current: 0.75
During the past 13 years, the highest Equity to Asset Ratio of Cell Impact was 0.88. The lowest was 0.11. And the median was 0.79.
OSTO:CI's Equity-to-Asset is ranked better than 81.76% of 3087
companies
in the Industrial Products industry
Industry Median: 0.56
vs OSTO:CI: 0.75
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cell Impact Equity-to-Asset Related Terms
Cell Impact Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Cell Impact's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:CI vs ATI, CRS, MLI: Equity-to-Asset Comparison
For the Metal Fabrication subindustry, Cell Impact's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cell Impact Equity-to-Asset vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Cell Impact's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cell Impact's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cell Impact's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cell Impact (OSTO:CI) has a Equity-to-Asset of 0.75 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cell Impact and its competitors. This is near median its historical median of 0.79. Over the past decade, Cell Impact's Equity-to-Asset has ranged from 0.11 to 0.88. According to the industry distribution chart, Cell Impact ranks #563 out of 3087 companies in the Industrial Products industry, placing it in the top 18.2%.
Is Cell Impact's Equity-to-Asset too high?
Cell Impact's current Equity-to-Asset of 0.75 is near median its 10-year median of 0.79. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 0.88. The Industrial Products industry median Equity-to-Asset is 0.56. Cell Impact's value of 0.75 is 33.9% above this industry median. Based on the distribution chart, Cell Impact ranks #563 out of 3087 companies in the Industrial Products industry, which is in the top quartile — a strong position relative to peers.
How does Cell Impact's Equity-to-Asset compare to ATI and CRS?
According to the Industrial Products industry distribution chart, Cell Impact ranks #563 out of 3087 companies for Equity-to-Asset. This places Cell Impact in the top 18% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.56. Cell Impact's value of 0.75 is 33.9% above this benchmark. Historically, Cell Impact's own Equity-to-Asset has ranged from 0.11 to 0.88 over the past decade. While the company's 10-year median is 0.79 vs. the industry median of 0.56, Cell Impact has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for an Industrial Products company?
The median Equity-to-Asset among Industrial Products companies is 0.56, based on 3,087 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cell Impact's current Equity-to-Asset of 0.75 is 33.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cell Impact and its competitors. For the Industrial Products industry, the median Equity-to-Asset is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cell Impact's current Equity-to-Asset is 0.75, which is near median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Impact stock overvalued right now?
Based on GuruFocus' analysis, Cell Impact (OSTO:CI) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.03, compared to a current price of kr0.04 — trading 46.3% above its estimated fair value. The current Equity-to-Asset is 0.75, which is near median its 10-year median of 0.79 and 33.9% above the Industrial Products industry median of 0.56. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cell Impact (OSTO:CI), the current Equity-to-Asset is 0.75 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cell Impact develops and manufactures flow plates for fuel cells and electrolyzers using materials such as graphite, stainless steel, and titanium. The company has developed and patented a high-velocity forming method, known as Cell Impact Forming, which enables the production of flow plates with advanced designs. Geographically, it operates in Sweden, Asia, the U.S., and Other Europe. It generates the majority of its revenue from Sweden.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:CI has been successfully added to your 
